Condition (MeSH)
Hydatidiform Mole
ClinicalTrials.gov lists 17 trials for Hydatidiform Mole or a narrower condition beneath it. Gynecologic Oncology Group has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 17 trials are tagged with Hydatidiform Mole itself; the rest are tagged with a narrower condition beneath it.
When did Hydatidiform Mole trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2018 | 1 |
| 2012 | 3 |
| 2011 | 1 |
| 2007 | 1 |
| 2006 | 1 |
| 2003 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hydatidiform Mole trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 6 |
How many Hydatidiform Mole trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 7 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hydatidiform Mole trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gynecologic Oncology Group | 3 |
| Eli Lilly and Company | 1 |
| Emergent BioSolutions | 1 |
| GOG Foundation | 1 |
| Nilratan Sircar Medical College | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Hydatidiform Mole? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Dactinomycin | 3 |
| Calcium Leucovorin | 2 |
| Amifostine | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HD- Methotrexate (MTX) | 4 |
| AG chemotherapy | 2 |
| Letrozol (Femara, Novartis) | 1 |
| Observational Intervention | 1 |
| Pemetrexe | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hydatidiform Mole trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 1 | 1 |
| Dyspnea | 1 | 1 |
| Psychiatric Disorders - Other | 1 | 1 |
Which publications cover Hydatidiform Mole? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| No evidence for mutations in NLRP7 and KHDC3L in women with androgenetic hydatidiform moles. | Prenatal diagnosis | 2013 | Yes |
| A recurrent intragenic genomic duplication, other novel mutations in NLRP7 and imprinting defects in recurrent biparental hydatidiform moles. | Molecular human reproduction | 2008 | Yes |
| The genetics of hydatidiform moles: new lights on an ancient disease. | Clinical genetics | 2007 | Yes |
| Analysis of the chromosomal region 19q13.4 in two Chinese families with recurrent hydatidiform mole. | Human reproduction (Oxford, England) | 2006 | Yes |
| Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. | Nature genetics | 2006 | Yes |
Showing 5 of 23 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hydatidiform mole | Annual incidence | Unknown | Worldwide | Not stated | Unspecified |
| Hydatidiform mole | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Hydatidiform mole | Annual incidence | Unknown | Worldwide | Not stated | Exact |
| Hydatidiform mole | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Hydatidiform mole | Annual incidence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hydatidiform mole | 99927 | Exact | Orphadata Science knowledge files, Product 1 |
| Hydatidiform mole | 99927 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.